Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 278

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 278
---
 will be repaid within 30 days at the earlier of:

| 1. | Receipt of a grant of 300,000 Euro from the Horizon 2020 Program, or |

| 2. | Consummation of the merger with OceanTech. |

The Company classified the loan as
a current liability and estimated repayment of the loan until March 31, 2024. In addition, as part of the loan agreement, the Company
issued to each lender warrants exercisable into ordinary shares of the Company (refer to Note 11).

The proceeds from the loan agreements
were allocated at the issuance date to the warrants and to the short-term loan. The warrants were measured at fair value and the remaining
amount allocated to the short-term loan. The short-term loan is subsequently measured at its amortized cost. Since issuance date to December
31, 2023, the Company recorded amortization of a discount as an interest expense of $173 for the short-term loan, within financial expense
line in the statements of comprehensive loss.

The following table presents the movement
in short term loan:

| Balance as of December 31, 2022               |     |   |    - |   |
|:----------------------------------------------|:----|:--|-----:|:--|
| Total principal payment                       |     |   |  325 |   |
| Debt discount related to issuance of warrants |     |   | (288 | ) |
| Amortization of loan discount                 |     |   |  173 |   |
| Balance as of December 31, 2023               |     | $ |  210 |   |

In April 2024, the Company received
the grant from the Horizon 2020 Program and as such, repaid the outstanding balance of the loan (refer to Note 14).

<div align='center'>F-29</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 6:- | CONVERTIBLE NOTES |

| a. | During 2020, the Company entered into various Convertible Loan Agreements (the “2020 CLAs”). As of December 31, 2020, the Company received $500 from the issuance of convertible notes (the “2020 Notes”) under the 2020 CLAs. In 2021, the Company received an additional $400. |

The 2020 Notes